Ribose 5-Phosphate Isomerase B Knockdown Compromises Trypanosoma brucei Bloodstream Form Infectivity
Open Access
- 8 January 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 9 (1) , e3430
Abstract
Ribose 5-phosphate isomerase is an enzyme involved in the non-oxidative branch of the pentose phosphate pathway, and catalyzes the inter-conversion of D-ribose 5-phosphate and D-ribulose 5-phosphate. Trypanosomatids, including the agent of African sleeping sickness namely Trypanosoma brucei, have a type B ribose-5-phosphate isomerase. This enzyme is absent from humans, which have a structurally unrelated ribose 5-phosphate isomerase type A, and therefore has been proposed as an attractive drug target waiting further characterization. In this study, Trypanosoma brucei ribose 5-phosphate isomerase B showed in vitro isomerase activity. RNAi against this enzyme reduced parasites' in vitro growth, and more importantly, bloodstream forms infectivity. Mice infected with induced RNAi clones exhibited lower parasitaemia and a prolonged survival compared to control mice. Phenotypic reversion was achieved by complementing induced RNAi clones with an ectopic copy of Trypanosoma cruzi gene. Our results present the first functional characterization of Trypanosoma brucei ribose 5-phosphate isomerase B, and show the relevance of an enzyme belonging to the non-oxidative branch of the pentose phosphate pathway in the context of Trypanosoma brucei infection. Within the non-oxidative branch of the pentose phosphate pathway, ribose 5-phosphate isomerase catalyzes the inter-conversion of ribose 5-phosphate and ribulose 5-phosphate. There are two types of ribose 5-phosphate isomerase, namely A and B. The presence of type B in Trypanosoma brucei, and its absence in humans, make this protein a promising drug target. African sleeping sickness is a serious parasitic disease that relies on limited chemotherapeutic options for control. In our study, a functional characterization of Trypanosoma brucei ribose 5-phosphate isomerase B is reported. Biochemical studies confirmed enzyme isomerase activity and its downregulation by RNAi affected mainly parasites infectivity in vivo. Overall this study shows that ribose 5-phosphate isomerase depletion is detrimental for parasites infectivity under host pressure.Keywords
This publication has 59 references indexed in Scilit:
- RNAi screening: new approaches, understandings, and organismsWIREs RNA, 2011
- High‐Throughput Analysis of an RNAi Library Identifies Novel Kinase Targets in Trypanosoma bruceiChemical Biology & Drug Design, 2011
- High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosomeGenome Research, 2011
- Requirement for acetyl‐CoA carboxylase in Trypanosoma brucei is dependent upon the growth environmentMolecular Microbiology, 2011
- The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase‐1 and blocks mitotic progression in bloodstream formsMolecular Microbiology, 2009
- The SWISS-MODEL Repository and associated resourcesNucleic Acids Research, 2008
- Phosphatidylethanolamine in Trypanosoma brucei Is Organized in Two Separate Pools and Is Synthesized Exclusively by the Kennedy PathwayJournal of Biological Chemistry, 2008
- Clustal W and Clustal X version 2.0Bioinformatics, 2007
- Ribose 5-phosphate isomerase type B from Trypanosoma cruzi: kinetic properties and site-directed mutagenesis reveal information about the reaction mechanismBiochemical Journal, 2006
- The SWISS-MODEL workspace: a web-based environment for protein structure homology modellingBioinformatics, 2005